Damora Therapeutics (DMRA) Preferred Stock Liabilities (2019 - 2026)

Damora Therapeutics has reported Preferred Stock Liabilities for 5 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Stock Liabilities fell 1.4% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 1.4% YoY), and the FY2025 full-year result was $1.3 million, down 1.4% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $1.3 million, roughly flat from $1.3 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $1.4 million in Q4 2024, with the low at $1.3 million in Q2 2025.
• Historically, Preferred Stock Liabilities has averaged $1.3 million across 3 years, with a median of $1.3 million in 2025.
• The largest YoY upside for Preferred Stock Liabilities was 1.4% in 2025 against a maximum downside of 1.4% in 2025.
• Damora Therapeutics' Preferred Stock Liabilities stood at $1.4 million in 2024, then fell by 1.4% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.